Page 3 - Adcendo Aps News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novo Seeds co-leads Adcendo s EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers
- Novo Seeds played instrumental role in supporting Adcendo from inception
- Plans to build a pipeline of ADCs directed at novel cancer targets
COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers. The EUR 51 million (US$ 62 million) Series A financing was led by Novo Seeds and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. ....

Jeroen Bakker , Niels Behrendt , Christoffer Nielsen , Santaris Pharma , Lars Henning Engelholm , Bioinnovation Institute , Finsen Laboratory Of Rigshospitalet , Finsen Laboratory , University Of Copenhagen , Bioinnovation Institute Creation House Program , Novo Nordisk Foundation , Novo Holdings , Enovo Seeds , Ysios Capital , Scientific Advisory , Henrik Stage , Chief Executive Officer , Creation House Program , John Lambert Phd , Vincent De Groot Phd , Murray Yule , பல்கலைக்கழகம் ஆஃப் கோபெந்ஹேகந் , நோவோ ஹோல்டிங்ஸ் , நோவோ விதைகள் , தலைமை நிர்வாகி அதிகாரி ,